Trial Profile
A Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Brexanolone (Primary)
- Indications Postnatal depression
- Focus Adverse reactions
- Acronyms CHICKADEE
- Sponsors Sage Therapeutics
- 03 Aug 2021 According to a SAGE Therapeutics media release, the company has announced the topline data from this study.
- 05 Feb 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned End Date changed from 1 Sep 2020 to 1 Jan 2021.